eHealth Based treatment of AdolescenT obesiTy with Low energy diet and sEmaglutide (eBATTLE Obesity)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506289-29-00

Enrollment

220

Registered

2023-11-16

Start date

2025-02-28

Completion date

Unknown

Last updated

2025-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

Percentage change in BMI (Time frame: From week 8 to week 60)

Detailed description

The main secondary endpoints include the number and severity of adverse events, physical activity, sleep, psychiatric symptoms, eating disorder symptoms, and health-related quality of life. In addition, changes in fat mass, fat-free mass, blood glucose, blood lipids, blood pressure, and other cardiometabolic risk factors will be compared between the treatment groups.

Interventions

DRUGSemaglutide placebo

DRUGSemaglutide B 3.0 mg/mL PDS290 or semaglutide placebo

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Percentage change in BMI (Time frame: From week 8 to week 60)	—

Secondary

Measure	Time frame
The main secondary endpoints include the number and severity of adverse events, physical activity, sleep, psychiatric symptoms, eating disorder symptoms, and health-related quality of life. In addition, changes in fat mass, fat-free mass, blood glucose, blood lipids, blood pressure, and other cardiometabolic risk factors will be compared between the treatment groups.	—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026